BMO Capital Markets Cuts Affimed (AFMD) Price Target to $4.00

Affimed (NASDAQ:AFMD) had its price objective reduced by equities research analysts at BMO Capital Markets from $6.00 to $4.00 in a report released on Thursday, August 9th. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential downside of 26.61% from the company’s previous close.

Several other analysts have also recently commented on the stock. ValuEngine upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Zacks Investment Research cut shares of Affimed from a “buy” rating to a “hold” rating in a research note on Thursday, April 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $3.75.

Shares of AFMD traded up $0.15 during trading hours on Thursday, reaching $5.45. 3,403,600 shares of the stock traded hands, compared to its average volume of 1,001,986. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.33 and a current ratio of 5.36. Affimed has a 52-week low of $1.15 and a 52-week high of $7.35. The stock has a market cap of $346.27 million, a price-to-earnings ratio of -6.99 and a beta of 2.35.

Several institutional investors have recently bought and sold shares of AFMD. Millennium Management LLC bought a new stake in shares of Affimed in the 1st quarter worth about $4,731,000. NEA Management Company LLC grew its holdings in Affimed by 32.1% during the 1st quarter. NEA Management Company LLC now owns 5,138,888 shares of the biopharmaceutical company’s stock valued at $9,507,000 after purchasing an additional 1,250,000 shares during the last quarter. Sabby Management LLC bought a new position in Affimed during the 1st quarter valued at about $787,000. Eversept Partners LLC bought a new position in Affimed during the 1st quarter valued at about $716,000. Finally, CVI Holdings LLC bought a new position in Affimed during the 1st quarter valued at about $667,000. Hedge funds and other institutional investors own 41.11% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

See Also: Asset Allocation and Your Retirement

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply